Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.TORC · Entity 6860 | Chief Medical Officer | December 06, 2019 | December 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date December 06, 2019 · Filed December 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,404,585 |
Reported balance
After 2019-12-06 transaction · row 1
1 source rowRow 1 · 2019-12-06 · Grant · Acquired 118,222 · Balance 1,404,585 F1: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.27 · Expires 2029-12-05 | Direct | 88,667 |
Reported balance
After 2019-12-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-06 · Grant · Acquired 88,667 · Balance 88,667 F3: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 600,000 |
Reported balance
Holding disclosure · report date 2019-12-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 600,000 F2: Shares held by the J.B. Mannick Irrevocable Trust (the "Trust"). The reporting person disclaims Section 16 beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
F2: Shares held by the J.B. Mannick Irrevocable Trust (the "Trust"). The reporting person disclaims Section 16 beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose
F3: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2019 Filed Dec 6, 2019 22:24 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 88,667 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000899243-19-028707 · doc4.xml · derivative · entry 3 Mannick Joan · CIK 0001727384 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,667 Underlying: Common Stock · 88,667 shares Expires 2029-12-05 F3 · derivative.exercise_date: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 06, 2019 Filed Dec 6, 2019 22:24 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantCommon Stock | 118,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028707 · doc4.xml · nonDerivative · entry 1 Mannick Joan · CIK 0001727384 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,404,585 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 22:37 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 93,000 | $0.00 Strike: $8.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005281 · doc4.xml · derivative · entry 1 Mannick Joan · CIK 0001727384 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: 25% of the shares shall vest on February 27, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| October 26, 2018 Filed Dec 18, 2018 02:11 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GiftCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031271 · doc4.xml · nonDerivative · entry 2 Mannick Joan · CIK 0001727384 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 600,000 F1 · ownership.nature: On October 26, 2018, the reporting person transferred 600,000 shares of common stock to the J.B. Mannick Irrevocable Trust (the "Trust"). The reporting person disclaims Section 16 beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. On July 23, 2018, the reporting person transferred 600,000 shares to a grantor retained annuity trust, which shares are included in the reporting person's direct ownership. Following this transfer, the reporting person directly held 1,286,363 shares and the Trust directly held 600,000 shares. Read SEC document |
| October 26, 2018 Filed Dec 18, 2018 02:11 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GiftCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031271 · doc4.xml · nonDerivative · entry 1 Mannick Joan · CIK 0001727384 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286,363 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.